Amplify Treatments, Testing and Advancements ETF
GERM
GERM was delisted on the 5th of September, 2024.
13 hedge funds and large institutions have $1.3M invested in Amplify Treatments, Testing and Advancements ETF in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.
19% less funds holding
Funds holding: 16 → 13 (-3)
25% less capital invested
Capital invested by funds: $1.72M → $1.3M (-$422K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$227K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$9.53K |
| 3 |
Morgan Stanley
New York
|
+$17 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$474K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$182K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$59.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$35.3K |
| 5 |
BAM
Byrne Asset Management
Kingston,
New Jersey
|
-$6K |
GERM Hedge Fund Activity: Q4 2023 in Review
13 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q4 2023, worth a combined $1.3M — down 25% from $1.72M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GERM and 1 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was Susquehanna International Group, adding an estimated $227K. The largest seller was Goldman Sachs, cutting an estimated $474K.
- 13 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q4 2023, down from 16 in Q3 2023.
- Funds reported $1.3M of Amplify Treatments, Testing and Advancements ETF stock for Q4 2023, down 25% quarter-over-quarter.
- 1 fund opened new Amplify Treatments, Testing and Advancements ETF positions in Q4 2023 and 4 closed out, a net change of -3 holders.
- The largest Amplify Treatments, Testing and Advancements ETF buyer in Q4 2023 was Susquehanna International Group, an estimated $227K added.
- The largest Amplify Treatments, Testing and Advancements ETF seller in Q4 2023 was Goldman Sachs, an estimated $474K sold.
Based on aggregated 13F filings for Q4 2023.